Episurf Medical Croissance future

Future contrôle des critères 2/6

Episurf Medical devrait augmenter ses bénéfices et son chiffre d'affaires de 8.4% et de 93.5% par an respectivement. Le BPA devrait croître de diminuer de 28.7% par an. Le rendement des capitaux propres devrait être -73% dans 3 ans.

Informations clés

8.4%

Taux de croissance des bénéfices

-28.7%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	33.0%
Taux de croissance des recettes	93.5%
Rendement futur des capitaux propres	-73.0%
Couverture par les analystes	Low
Dernière mise à jour	28 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Apr 03

We Think Some Shareholders May Hesitate To Increase Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation

May 03

Prévisions de croissance des bénéfices et des revenus

OM:EPIS B - Estimations futures des analystes et données financières antérieures (SEK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	523	-65	-65	-60	1
12/31/2025	208	-68	-65	-62	1
12/31/2024	132	-74	-74	-68	1
9/30/2024	13	-80	-85	-79	N/A
6/30/2024	12	-85	-92	-84	N/A
3/31/2024	11	-92	-93	-85	N/A
12/31/2023	10	-95	-94	-85	N/A
9/30/2023	1	-97	-96	-85	N/A
6/30/2023	2	-94	-88	-77	N/A
3/31/2023	5	-84	-85	-74	N/A
12/31/2022	7	-77	-81	-69	N/A
9/30/2022	14	-72	-74	-63	N/A
6/30/2022	12	-71	-72	-62	N/A
3/31/2022	9	-69	-70	-61	N/A
12/31/2021	7	-69	-67	-60	N/A
9/30/2021	7	-67	-63	-58	N/A
6/30/2021	7	-66	-61	-56	N/A
3/31/2021	5	-63	-60	-55	N/A
12/31/2020	5	-64	-59	-54	N/A
9/30/2020	5	-66	-63	-58	N/A
6/30/2020	5	-69	-63	-59	N/A
3/31/2020	5	-73	-66	-61	N/A
12/31/2019	5	-70	-65	-59	N/A
9/30/2019	5	-66	-62	-55	N/A
6/30/2019	5	-62	-69	-61	N/A
3/31/2019	4	-59	-62	-54	N/A
12/31/2018	4	-58	-62	-52	N/A
9/30/2018	4	-58	-64	-55	N/A
6/30/2018	3	-59	N/A	-49	N/A
3/31/2018	3	-55	N/A	-62	N/A
12/31/2017	3	-61	N/A	-61	N/A
9/30/2017	3	-64	N/A	-59	N/A
6/30/2017	2	-65	N/A	-59	N/A
3/31/2017	2	-69	N/A	-53	N/A
12/31/2016	2	-62	N/A	-56	N/A
9/30/2016	7	-57	N/A	-55	N/A
6/30/2016	8	-53	N/A	-50	N/A
3/31/2016	7	-48	N/A	-44	N/A
12/31/2015	7	-44	N/A	-38	N/A
9/30/2015	2	-38	N/A	-34	N/A
6/30/2015	2	-34	N/A	-34	N/A
3/31/2015	2	-32	N/A	-30	N/A
12/31/2014	2	-33	N/A	-32	N/A
9/30/2014	3	-31	N/A	-31	N/A
6/30/2014	2	-28	N/A	-31	N/A
3/31/2014	2	-26	N/A	-25	N/A
12/31/2013	2	-23	N/A	-21	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: EPIS B devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: EPIS B devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: EPIS B devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de EPIS B ( 93.5% par an) devrait croître plus rapidement que le marché Swedish ( 0.03% par an).

Croissance élevée des revenus: Le chiffre d'affaires de EPIS B ( 93.5% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: EPIS B devrait être non rentable dans 3 ans.

Episurf Medical Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates increase by 850%, EPS downgraded

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus EPS estimates fall by 14%

Consensus revenue estimates decrease by 19%

Price target decreased by 27% to kr4.00

Consensus revenue estimates fall by 20%

Recent updates

Consensus revenue estimates increase by 850%, EPS downgraded

Episurf Medical AB (publ) to Report Fiscal Year 2024 Results on Mar 06, 2025

Third quarter 2024 earnings released: kr0.024 loss per share (vs kr0.078 loss in 3Q 2023)

Episurf Medical AB (publ) to Report Q2, 2025 Results on Jul 11, 2025

Chief Executive Officer recently bought kr2.3m worth of stock

New major risk - Market cap size

Consensus revenue estimates decrease by 22%, EPS upgraded

Second quarter 2024 earnings released: kr0.03 loss per share (vs kr0.11 loss in 2Q 2023)

New major risk - Shareholder dilution

Episurf Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 90.158983 million.

Independent Director recently bought kr129k worth of stock

Insufficient new directors

Consensus EPS estimates fall by 14%

First quarter 2024 earnings released: kr0.077 loss per share (vs kr0.087 loss in 1Q 2023)

New major risk - Market cap size

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Full year 2023 earnings: EPS and revenues miss analyst expectations

Here's Why Episurf Medical (STO:EPIS B) Must Use Its Cash Wisely

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Episurf Medical AB (Publ) Receives Four Additional Patent Approval Notification

Is Episurf Medical (STO:EPIS B) In A Good Position To Invest In Growth?

Consensus revenue estimates decrease by 19%

Price target decreased by 27% to kr4.00

Third quarter 2023 earnings released

Episurf Medical AB (publ), Annual General Meeting, Apr 09, 2024

Episurf Medical Announces 510(k) Submission for Big Toe Implant

Episurf Members Announces Nomination Committee for Episurf Medical's Annual General Meeting in 2024

Episurf Medical Announces Early Clinical Results from Episealer Talus Study Presented at Scientific Congress

Episurf Medical Announces Prospective Episealer Talus Clinical Study

Episurf Medical AB (publ) Announces First Commercial Case in the US Has Been Scheduled for Surgery

Second quarter 2023 earnings released

Chief Executive Officer recently bought kr660k worth of stock

Will Episurf Medical (STO:EPIS B) Spend Its Cash Wisely?

First quarter 2023 earnings released

Chief Executive Officer recently bought kr72k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Episurf Medical AB (publ), Annual General Meeting, May 04, 2023

Episurf Medical AB (publ) Announces Dennis Stripe Not Stand for Re-Election as Chairman of the Board of Directors

Episurf Medical AB (Publ) Receives Notice of Allowance from the United States Patent and Trademark Office

Episurf Medical AB (publ) Receives FDA 510(k) clearance for Episealer® Patellofemoral System

Consensus revenue estimates fall by 20%

Third quarter 2022 earnings released

Price target decreased to kr5.65

Episurf Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 09, 2024

Episurf Medical Announces That the Episealer® Knee Technology and Clinical Results

Episurf Medical AB (Publ) Appoints Nomination Committee

We're Not Very Worried About Episurf Medical's (STO:EPIS B) Cash Burn Rate

Episurf Medical AB (Publ) Provides Update on 510(K) Application to FDA for the Episealer Patellofemoral System

Episurf Medical Announces New U.S. Patent Approval for Episurf Medical

Episurf Medical AB (Publ) Announces New Patent Approval in Hong Kong for Episurf Medical

Episurf Medical Announces Results from Study with Episealer® Knee Implant Accepted for Presentation at Swedish Orthopaedic Congress

Consensus forecasts updated

Episurf Medical AB (Publ) Announces New Patent Approval in Hong Kong

Second quarter 2022 earnings released

Episurf Medical AB (Publ) Announces First Surgery in India with the Knee Implant Episealer® Has Been Scheduled

First quarter 2022 earnings: Revenues miss analyst expectations

Price target decreased to kr5.65

Episurf Medical Provides Updates of 510(K) Application on Episealer Patellofemoral System

New European Patent Approves for Episurf Medical

Episurf Medical AB (Publ) Announces the Initiation of a Prospective Investigator-Initiated Study with 2 Years Follow-Up of 25 Episealer Talus Patients

First Indian Patent Approval for Episurf Medical

Episurf Medical Receives Reimbursement Coverage for Episealer Talus in Belgium

Episurf Medical AB’s Implants Receive National Regulatory Approval in Hong Kong

Consensus revenue estimates fall by 34%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

The European Patent Office Approves European Patent for Episurf Medical

the European Patent Office EPO Announces Its Intention to Grant Another European Patent for Episurf Medical AB (publ)